Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T18:14:21.081Z Has data issue: false hasContentIssue false

National differences in disulfiram prescribing

Published online by Cambridge University Press:  02 January 2018

Jonathan Chick*
Affiliation:
University of Edinburgh, Royal Edinburgh Hospital Edinburgh EH10 5HF
Colin Brewer
Affiliation:
The Stapleford Centre, London SW1 9PN
*
∗ Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Aims and method

To test the impression of wide national differences in the use of deterrent medication in the treatment of alcohol dependence, data showing comparative sales of disulfiram in 13 countries were obtained.

Results

Sales in Britain were lowest, and less than a tenth of those in Denmark. Rates bore no relation to alcohol sales or an index of alcohol-related problems in the 13 countries.

Clinical implications

British doctors may apply a particularly cautious risk/benefit ratio for disulfiram. The disparity may also reflect the predominantly nonmedical approach to treating alcohol dependence in Britain.

Information

Type
Original papers
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 The Royal College of Psychiatrists
Submit a response

eLetters

No eLetters have been published for this article.